Orkambi’s cost too high for benefit offered, says NICE
17 June 2016 | By Victoria White, Digital Content Producer
NICE has said it will not be able to recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis...
List view / Grid view
17 June 2016 | By Victoria White, Digital Content Producer
NICE has said it will not be able to recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis...
1 June 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has asked Janssen to set out a case for including its chronic lymphocytic leukaemia (CLL) drug ibrutinib (Imbruvica) in the Cancer Drugs Fund (CDF).
25 May 2016 | By Victoria White, Digital Content Producer
Jevtana has been recommended in combination with other drugs as a treatment option for metastatic hormone-relapsed prostate cancer in England...
25 May 2016 | By Victoria White, Digital Content Producer
NICE has published final guidance recommending three drugs for treating type 2 diabetes: canagliflozin, dapagliflozin and empagliflozin...
12 May 2016 | By Victoria White, Digital Content Producer
In draft guidance, NICE has said ‘no’ to Opdivo for the treatment of patients with non-squamous NSCLC whose disease has progressed after prior chemotherapy...
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Humira (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy.
6 May 2016 | By Victoria White, Digital Content Producer
Alirocumab and evolocumab are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia...
4 May 2016 | By Victoria White, Digital Content Producer
NICE has allowed extra time for further discussions on access arrangements for PTC Therapeutics’ Translarna (ataluren) for Duchenne Muscular Dystrophy...
3 May 2016 | By Victoria White, Digital Content Producer
NICE has published final draft guidance recommending trametinib in combination with dabrafenib to treat some patients with melanoma...
27 April 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Entresto (sacubitril valsartan) for some people with heart failure.
27 April 2016 | By Victoria White, Digital Content Producer
The guidance recommends paclitaxel and PLDH for treating ovarian cancer that has returned after previous chemotherapy treatment...
22 April 2016 | By Victoria White, Digital Content Producer
NICE has issued final guidance recommending Sanofi’s Jevtana (cabazitaxel) for some prostate cancer patients...
18 April 2016 | By Victoria White, Digital Content Producer
NICE has recommended Translarna (ataluren) for treating children aged 5 and over with Duchenne muscular dystrophy caused by a nonsense mutation...
13 April 2016 | By Victoria White, Digital Content Producer
NICE has issued guidance advising the best ways of ensuring controlled drugs such as morphine, methadone and diazepam are used safely and responsibly...
21 March 2016 | By Victoria White
Professor Paul Workman of The Institute of Cancer Research, which discovered abiraterone, said the recommendation was “a big victory for men"...